HC Wainwright Has Bullish Estimate for VERV FY2025 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV) – Analysts at HC Wainwright lifted their FY2025 EPS estimates for Verve Therapeutics in a research note issued to investors on Monday, May 19th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($2.16) for the year, up from their previous forecast of ($2.38). HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Verve Therapeutics’ Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.68) EPS and Q4 2026 earnings at ($0.70) EPS.

A number of other research firms also recently commented on VERV. Royal Bank of Canada cut their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday, March 4th. Cantor Fitzgerald raised shares of Verve Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, April 15th. Guggenheim lifted their target price on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, April 15th. William Blair reaffirmed an “outperform” rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Finally, Canaccord Genuity Group lifted their target price on shares of Verve Therapeutics from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Tuesday, April 15th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $25.75.

Verve Therapeutics Trading Down 8.2%

NASDAQ:VERV opened at $4.23 on Wednesday. Verve Therapeutics has a 12 month low of $2.86 and a 12 month high of $9.31. The company has a market cap of $377.07 million, a PE ratio of -1.72 and a beta of 1.82. The company has a 50 day simple moving average of $4.68 and a two-hundred day simple moving average of $5.83.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.36. The company had revenue of $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Norges Bank purchased a new position in shares of Verve Therapeutics during the 4th quarter worth $441,000. Wells Fargo & Company MN lifted its stake in shares of Verve Therapeutics by 25.0% during the 4th quarter. Wells Fargo & Company MN now owns 45,422 shares of the company’s stock valued at $256,000 after buying an additional 9,083 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in shares of Verve Therapeutics by 465.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 42,781 shares of the company’s stock valued at $241,000 after buying an additional 35,214 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Verve Therapeutics by 5.7% during the 4th quarter. Invesco Ltd. now owns 57,140 shares of the company’s stock valued at $322,000 after buying an additional 3,080 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Verve Therapeutics by 1.9% during the 4th quarter. Rhumbline Advisers now owns 111,203 shares of the company’s stock valued at $627,000 after buying an additional 2,093 shares in the last quarter. Hedge funds and other institutional investors own 97.11% of the company’s stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.